Meta Biomed Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Meta Biomed has a total shareholder equity of ₩82.6B and total debt of ₩56.5B, which brings its debt-to-equity ratio to 68.4%. Its total assets and total liabilities are ₩167.9B and ₩85.3B respectively. Meta Biomed's EBIT is ₩12.4B making its interest coverage ratio 5.1. It has cash and short-term investments of ₩45.3B.
Belangrijke informatie
68.4%
Verhouding schuld/eigen vermogen
₩56.48b
Schuld
Rente dekkingsratio | 5.1x |
Contant | ₩45.35b |
Aandelen | ₩82.57b |
Totaal verplichtingen | ₩85.30b |
Totaal activa | ₩167.87b |
Recente financiële gezondheidsupdates
Recent updates
Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%
Feb 26Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend
Apr 11Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years
Mar 14Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?
Feb 03Is Meta Biomed (KOSDAQ:059210) A Risky Investment?
Jan 13Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock
Dec 26Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years
Dec 08Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 20Analyse van de financiële positie
Kortlopende schulden: A059210's short term assets (₩81.0B) exceed its short term liabilities (₩71.7B).
Langlopende schulden: A059210's short term assets (₩81.0B) exceed its long term liabilities (₩13.6B).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: A059210's net debt to equity ratio (13.5%) is considered satisfactory.
Schuld verminderen: A059210's debt to equity ratio has reduced from 71.4% to 68.4% over the past 5 years.
Schuldendekking: A059210's debt is well covered by operating cash flow (33.6%).
Rentedekking: A059210's interest payments on its debt are well covered by EBIT (5.1x coverage).